Trastuzumab in metastatic breast cancer

Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.

Metastatic breast cancer; Trastuzumab; HER2

[1] Chazin et al.: "Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor". Oncogene, 1992, 7, 1859.

[2] Heldin C.H.: "Dimerization of cell surface receptors in signal transduction". Cell, 1995, 80, 213.

[3] Blume-Jensen P., Hunter T.: "Oncogene kinase signalling". Nature, 2001, 411, 355.

[4] Slamon D.J. et al.: "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene". Science, 1987, 235, 177.

[5] Slamon D.J. et al.: "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer". Science, 1989, 244, 707.

[6] Jiminez R.E. et al.: "Determination of HER-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization". Mod. Pathol., 2000, 13, 37.

[7] Lebeau A. et al.: "HER/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridisation". J. Clin. Oneal., 2001, 19, 354.

[8] Wang S. et al.: "Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: Comparison of immunoistochemestry assay with fluorescence in situ hybridization assays". J. Clin. Pathol., 2000, 53, 374.

[9] Bast R.C. et al.: "American Oncology Tumor Markers Expert P anel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancerar: Clinical practice guidelines of the American Society of Clinical Oncology". J. Clin. Oneal., 2001, 19, 1865.

[10] Schneider J.W. et al.: "Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study". Semin. Oneal., 2002, 29, 3 (suppl. 11), 22.

[11] Lee K.F. et al.: "Requirement for neureguling receptor HER-2/erbB2 in neural and cardiac development". Nature, 1995, 378, 394.

[12] Cobleigh M., Vogel C. et al.: "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease". J. Clin. Oneal., 1999, 17, 2639.

[13] Vogell C., Cobleigh M. et al.: "Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpressing metastatic breast cancer". J. Clin. Oneal., 2002, 20, 719.

[14] Konecnyg et al.: "Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression" (abstract). Breast Cancer Res. Treat., 1999, 57, 114.

[15] Chou T.C., Talay P.: "Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors". Adv. Enzyme Regul., 1984, 22, 27.

[16] Burstein H. et al.: "Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer". J. Clin. Oncol., 2001, 19, 2722.

[17] Seidman A.D. et al.: "HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer (MBC)". Proc. Am. Soc. Clin. Oneal., 1996, 15, 104.

[18] Uber Ket al.: "A phase II trial of weekly docetaxel and herceptin as first- or second-line treatment in HER2 over-expressing metastatic breast cancer" (abstract). Proc. Am. Soc. Clin. Oneal., 20, 50b, 201.

[19] Burris H.: "Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer". Semin. Oncol., 2001, 28, 38.

[20] Bangemann N. et al.: "T reatment of HER2 overexpressing metastatic breast cancer with trastuzumab and chemotherapy" (abstract). Breast Cancer Res. Treat., 2000, 64, 23.

[21] Bangemann N. et al.: "Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC)" (abstract). Ann. Oneal., 2000, 11 (suppl. 4), 143.